GSK (LON:GSK) Insider Luke Miels Sells 4,549 Shares

GSK plc (LON:GSK) insider Luke Miels sold 4,549 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of GBX 2,211, for a total value of £100,578.39.

GSK Stock Down 0.7%

GSK stock traded down GBX 15 during trading on Wednesday, hitting GBX 2,153. 121,524,398 shares of the company’s stock were exchanged, compared to its average volume of 12,884,935. The business has a 50-day moving average price of GBX 1,861.08 and a two-hundred day moving average price of GBX 1,682.05. The company has a current ratio of 0.81, a quick ratio of 0.73 and a debt-to-equity ratio of 114.64. The stock has a market capitalization of £86.87 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 1.24 and a beta of 0.31. GSK plc has a 52-week low of GBX 1,242.50 and a 52-week high of GBX 2,219.

GSK (LON:GSK) last announced its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, equities research analysts expect that GSK plc will post 175.980975 EPS for the current year.

Wall Street Analyst Weigh In

GSK has been the topic of several research reports. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a report on Thursday, January 15th. UBS Group reissued a “neutral” rating and set a GBX 1,940 price objective on shares of GSK in a research report on Friday, January 23rd. Shore Capital Group reaffirmed a “buy” rating and issued a GBX 2,300 target price on shares of GSK in a report on Wednesday, February 4th. Finally, Jefferies Financial Group reissued a “buy” rating and set a GBX 2,100 price target on shares of GSK in a report on Wednesday, January 7th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of GBX 1,917.86.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.